<DOC>
	<DOCNO>NCT01172002</DOCNO>
	<brief_summary>Leflunomide versus Azathioprine Maintenance Therapy Lupus Nephritis</brief_summary>
	<brief_title>Leflunomide Versus Azathioprine Maintenance Therapy Lupus Nephritis</brief_title>
	<detailed_description>Proliferative glomerulonephritis common severe manifestation systemic lupus erythematosus ( SLE ) usually require intensive therapy high dos glucocorticosteroids cytotoxic drug , intravenous ( IV ) cyclophosphamide ( CYC ) . The objective Trial compare leflunomide ( LEF ) azathioprine ( AZA ) , term efficacy toxicity , remission-maintaining treatment proliferative lupus glomerulonephritis , remission-inducing therapy short-course IV CYC regimen . The hypothesis trial LEF non-inferior AZA .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Aged 18 65 year Biopsyproven proliferative lupus nephritis Disease activity , SLEDAI score ≥ 8 point Persistent proteinuria ( ≥ 1g/24h ) , without microscopic hematuria ; Signed informed consent Allergy LEF , CTX , AZA Recent treatment highdose glucocorticoid Weight &lt; 45kg Recent treatment immunosuppressive drug CNS ( Central Nerve System ) Lupus patient Hepatic failure patient Severely abnormal renal function endstage renal failure More exclusion criterion protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Leflunomide</keyword>
	<keyword>Azathioprine</keyword>
</DOC>